Home/Pipeline/αDBS System

αDBS System

Parkinson's Disease

ApprovedActive

Key Facts

Indication

Parkinson's Disease

Phase

Approved

Status

Active

Company

Newronika

About Newronika

Newronika is a pioneering medical device company commercializing a next-generation, adaptive deep brain stimulation (αDBS) system for Parkinson's disease. Its technology differentiates itself from conventional DBS by using a closed-loop system that continuously senses brain signals and automatically adjusts stimulation, aiming to improve symptom control while reducing side effects. The company has achieved CE Mark approval in Europe and is generating early revenue through commercial sales, supported by compelling clinical data showing strong patient preference. Newronika is positioned to challenge the standard of care in neuromodulation with its intelligent, data-driven platform.

View full company profile

Therapeutic Areas

Parkinson's Disease Neurology

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active